Tidied up the log-scale chart. DYOR.
Price has been within this channel on the log chart for the last 19 months. With a busy year ahead and pre-clinical and proof of concept trial activity to show value, I think price will continue to track within the channel. Some observations:
The rerate is management execution in action, beating the company and the company plans into shape and setting it up with the potential for delivering amazing value for shareholders.
- A 12-month move along the centre-line of the channel would be approximately 1,300% move in the share price (a share price around $43).
- The current 1-year return (from marketindex.com.au) is 925%.
Looking at the transactions covering the Synthorx, Forty Seven and Immunomedics we really area entering the sweet-spot for a buyout. It's important to understand the context of the historic results and approval for AML, the historic data for Breast Cancer and the recent preclinical data for Breast Cancer. We are expecting further preclinical data for FTO, Breast Cancer and possibly for AML.
Read the following posts for context of value of peer transactions:
https://hotcopper.com.au/posts/50767529/single
https://hotcopper.com.au/posts/50911717/single
RAC - Charts & Price Action, page-3702
-
- There are more pages in this discussion • 18,165 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.43 |
Change
0.060(4.40%) |
Mkt cap ! $245.3M | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.50 | $1.35 | $131.6K | 92.98K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 2501 | $1.42 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.43 | 5038 | 1 |
View Market Depth
| Last trade - 14.52pm 06/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |